Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity

Cited by (1,000)

Items 601–700 of 1,000

1. Induced-fit docking and binding free energy calculation on furostanol saponins from Tupistra chinensis as epidermal growth factor receptor inhibitors
   Huajun Luo, Junzhi Wang, Wei Deng, Kun Zou · 2013 · Medicinal Chemistry Research
2. Hydration effects on the efficacy of the Epidermal growth factor receptor kinase inhibitor afatinib
   Srinivasaraghavan Kannan, Mohan R. Pradhan, Garima Tiwari, Wei-Chong Tan, Balram Chowbay, Eng Huat Tan, Daniel Shao-Weng Tan, Chandra Shekhar Verma · 2017 · Scientific Reports
3. SKLB188 inhibits the growth of head and neck squamous cell carcinoma by suppressing EGFR signalling
   Mansoureh Barzegar, Shuang Ma, Chao Zhang, Xin Chen, Ying Gu, Chaowei Shang, Xiaojuan Jiang, Jiao Yang, Cherie‐Ann O. Nathan, Shengyong Yang et al. · 2017 · British Journal of Cancer
4. Genotyping of common EGFR mutations in lung cancer patients by electrochemical biosensor
   Xiuhua Weng, Xiongwei Xu, Changlian Wang, Wei-Wei Lin, Ai‐Lin Liu, Wei Chen, Xinhua Lin · 2017 · Journal of Pharmaceutical and Biomedical Analysis
5. Discovery of 4-((N-(2-(dimethylamino)ethyl)acrylamido)methyl)-N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)benzamide (CHMFL-PDGFR-159) as a highly selective type II PDGFRα kinase inhibitor for PDGFRα driving chronic eosinophilic leukemia
   Qiang Wang, Feiyang Liu, Shuang Qi, Ziping Qi, Xiao-E Yan, Beilei Wang, Aoli Wang, Wei Wang, Chen Cheng, Xiaochuan Liu et al. · 2018 · European Journal of Medicinal Chemistry
6. In-situ and highly sensitive detection of epidermal growth factor receptor mutation using nano-porous quartz crystal microbalance
   Hyunjun Park, Juneseok You, Chanho Park, Kuewhan Jang, Sungsoo Na · 2018 · Journal of Mechanical Science and Technology
7. Revisiting the molecular mechanism of acquired resistance to reversible tyrosine kinase inhibitors caused by EGFR gatekeeper T790M mutation in non-small-cell lung cancer
   Yan Hong Zhao, Yingjie Jiao, Fengzhe Sun, Xudong Liu · 2018 · Medicinal Chemistry Research
8. Computational approaches for identifying potential inhibitors on targeting protein interactions in drug discovery
   Vishnupriya Kanakaveti, Shanmugam Anusuya, C. V. Ramakrishnan, P. Anoosha, Ramasamy Sakthivel, Suresh Kumar Rayala, M. Michael Gromiha · 2020 · Advances in protein chemistry and structural biology
9. Identification of a novel nitroflavone-based scaffold for designing mutant-selective EGFR tyrosine kinase inhibitors targeting T790M and C797S resistance in advanced NSCLC
   Cristina Minnelli, Emiliano Laudadio, Leonardo Sorci, Giulia Sabbatini, Roberta Galeazzi, Adolfo Amici, Marta Stefania Semrau, Paola Storici, Samuele Rinaldi, Pierluigi Stipa et al. · 2022 · Bioorganic Chemistry
10. Molecular docking studies of Traditional Chinese Medicinal compounds against known protein targets to treat non-small cell lung carcinomas
    Guofang Zhao, Zuoan Huang, Xuekui Du, Minglei Yang, Dandan Huang, Shun Zhang · 2016 · Molecular Medicine Reports
11. Structural analysis of the EGFR TK domain and potential implications for EGFR targeted therapy
    Donghai Li · 2012 · International Journal of Oncology
12. Winning the Arms Race by Improving Drug Discovery against Mutating Targets
    Amy C. Anderson · 2011 · ACS Chemical Biology
13. The Therapeutic Potential of the Restoration of the p53 Protein Family Members in the EGFR-Mutated Lung Cancer
    Matilde Fregni, Yari Ciribilli, Joanna Zawacka‐Pankau · 2022 · International Journal of Molecular Sciences
14. Anti-proliferative activity, molecular genetics, docking analysis, and computational calculations of uracil cellulosic aldehyde derivatives
    Asmaa Mahmoud Fahim, Sawsan Dacrory, Ghada H. Elsayed · 2023 · Scientific Reports
15. PDZK1 suppresses TNBC development and sensitizes TNBC cells to erlotinib via the EGFR pathway
    Yuanzhen Ma, Zhiyu Fang, Hongning Zhang, Yijun Qi, Yuke Mao, Junfang Zheng · 2024 · Cell Death and Disease
16. NPGPT: natural product-like compound generation with GPT-based chemical language models
    Koh Sakano, Kairi Furui, Masahito Ohue · 2024 · The Journal of Supercomputing
17. Structure-based ensemble-QSAR model: a novel approach to the study of the EGFR tyrosine kinase and its inhibitors
    Xianqiang Sun, Lei Chen, Yao-zong Li, Weihua Li, Guixia Liu, Yaoquan Tu, Yun Tang · 2013 · Acta Pharmacologica Sinica
18. 6‐Aryl and Heterocycle Quinazoline Derivatives as Potent EGFR Inhibitors with Improved Activity toward Gefitinib‐Sensitive and ‐Resistant Tumor Cell Lines
    Mostafa M. Hamed, Dalal A. Abou El Ella, Adam B. Keeton, Gary Anthony Piazza, Alireza Abadi, Rolf W. Hartmann, Matthias Engel · 2013 · ChemMedChem
19. Truncated structures used in search for new lead compounds and in a retrospective analysis of thienopyrimidine-based EGFR inhibitors
    Steffen Bugge, Ingri Ullestad Moen, Kent-Ove Kragseth Sylte, Eirik Sundby, Bård Helge Hoff · 2015 · European Journal of Medicinal Chemistry
20. Concomitant EGFR Inhibitors Combined with Radiation for Treatment of Non-small Cell Lung Carcinoma
    Dejie Zheng, Guohua Yu, Jianfeng Gao, Jun-Dong Gu · 2013 · Asian Pacific Journal of Cancer Prevention
21. Photodynamic targeting of EGFR does not predict the treatment outcome in combination with the EGFR tyrosine kinase inhibitor Tyrphostin AG1478
    Anette Weyergang, Olav Kaalhus, Kristian Berg · 2008 · Photochemical & Photobiological Sciences
22. Strategies to Overcome Acquired Resistances Conferred by Mutations in the Kinase Domain of Egfr
    Sang Min Lim, Yujeong Jeong, Sungwoo Hong · 2016 · Future Medicinal Chemistry
23. Staurosporine Derivatives Generated by Pathway Engineering in a Heterologous Host and Their Cytotoxic Selectivity
    Fei Xiao, Huayue Li, Mingyuan Xu, Tong Li, Ju Wang, Chaomin Sun, Kui Hong, Wenli Li · 2018 · Journal of Natural Products
24. Design, synthesis, and biological evaluation of quinazoline derivatives containing piperazine moieties as antitumor agents
    Wen Li, Shu-Yi Chen, Weinan Hu, Mei Ju Zhu, Jiamin Liu, Yihong Fu, Zhenchao Wang, Guiping Ouyang · 2020 · Journal of Chemical Research
25. Synthesis, Characterization, and Cytotoxicity of Morpholine-Containing Ruthenium(II) p-Cymene Complexes
    Rishav Chatterjee, Indira Bhattacharya, Souryadip Roy, Kallol Purkait, Tuhin Subhra Koley, Arnab Gupta, Arindam Mukherjee · 2021 · Inorganic Chemistry
26. Endothelial PAS domain-containing protein 1 confers TKI-resistance by mediating EGFR and MET pathways in non-small cell lung cancer cells
    Qiang Zhen, Junfeng Liu, Jia-Bao Liu, Renfeng Wang, Wei-Wei Chu, Ya-Xiao Zhang, Guo-Liang Tan, Xiao-Jian Zhao, Baolei Lv · 2015 · Cancer Biology & Therapy
27. Afatinib and lung cancer
    Prantesh Jain, Rashmi Khanal, Aakanksha Sharma, Feng Yan, Neelesh Sharma · 2014 · Expert Review of Anticancer Therapy
28. Mechanism of Drug Efficacy Within the EGF Receptor Revealed by Microsecond Molecular Dynamics Simulation
    Shunzhou Wan, David W. Wright, Peter V. Coveney · 2012 · Molecular Cancer Therapeutics
29. Deguelin Potentiates Apoptotic Activity of an EGFR Tyrosine Kinase Inhibitor (AG1478) in PIK3CA-Mutated Head and Neck Squamous Cell Carcinoma
    Yuh Baba, T Maeda, Atsuko Suzuki, Satoshi Takada, Masato Fujii, Yukio Kato · 2017 · International Journal of Molecular Sciences
30. The Role of Molecular Diagnostics in Cancer Diagnosis and Treatment
    Luka Ozretić, Lukas Carl Heukamp, Margarete Odenthal, Reinhard Buettner · 2012 · Onkologie
31. Ligand-Based Pharmacophore Screening Strategy: a Pragmatic Approach for Targeting HER Proteins
    Nivya James, K. Ramanathan · 2018 · Applied Biochemistry and Biotechnology
32. A Structural Insight Into Two Important ErbB Receptors (EGFR and HER2) and Their Relevance to Non‐Small Cell Lung Cancer
    Edanur Topalan, Ahmet Büyükgüngör, Melih Çiğdem, S Futóné Gura, Belgin Sever, Masami Otsuka, Mikako Fujita, Hasan DeMi̇rci̇, Halil I. Ciftci · 2025 · Archiv der Pharmazie
33. Computational insights into the stereo-selectivity of catechins for the inhibition of the cancer therapeutic target EGFR kinase
    Mohd Rehan, Firoz Ahmed, Mohammad Imran Khan, Hifzur Rahman Ansari, Shazi Shakil, Moustafa E. El‐Araby, Salman Bakr I. Hosawi, Mohammad Saleem · 2024 · Frontiers in Pharmacology
34. Glycaemic abnormalities induced by small molecule tryosine kinase inhibitors: a review
    Takudzwa Mugiya, Mmamosheledi E. Mothibe, Andile Khathi, Phikelelani Siphosethu Ngubane, Ntethelelo Hopewell Sibiya · 2024 · Frontiers in Pharmacology
35. Design and synthesis of some new imidazole-morpholine-1,2,4-oxadiazole hybrids as EGFR targeting in vitro anti-breast cancer agents
    Praveen kumar Kannekanti, Satheesh Kumar Nukala, Srinivas Bandari, Mandala Jyothi, Ravinder Manchal, Narasimha Swamy Thirukovela · 2024 · Journal of Molecular Structure
36. N2-Trimethylacetyl substituted and unsubstituted-N4-phenylsubstituted-6-(2-pyridin-2-ylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamines: Design, cellular receptor tyrosine kinase inhibitory activities and in vivo evaluation as antiangiogenic, antimetastatic and antitumor agents
    Aleem Gangjee, Ojas A. Namjoshi, Jianming Yu, Michael A. Ihnat, Jessica E. Thorpe, Lora C. Bailey‐Downs · 2013 · Bioorganic & Medicinal Chemistry
37. Rapid and Efficient Detection of EGFR Mutations in Problematic Cytologic Specimens by High-Resolution Melting Analysis
    Katarina Hlinkova, Pavel Babál, Peter Berzinec, Ivan Majer, Denisa Ilenčíková · 2011 · Molecular Diagnosis & Therapy
38. Identifying advanced stage NSCLC patients who benefit from afatinib therapy using 18F-afatinib PET/CT imaging
    Eveline Annette van de Stadt, Maqsood M. Yaqub, Adriaan A. Lammertsma, Alex J. Poot, Robert C. Schuit, Sharon Remmelzwaal, Lothar Andreas Schwarte, Egbert Frederik Smit, Harry Hendrikse, Idris Bahce · 2021 · Lung Cancer
39. Synthesis and Antitumor Evaluation of Menthone-Derived Pyrimidine-Urea Compounds as Potential PI3K/Akt/mTOR Signaling Pathway Inhibitor
    Mei Juan Huang, Wengui Duan, Naiyuan Chen, Guishan Lin, Xiu Wang · 2022 · Frontiers in Chemistry
40. Cell-penetrating peptides containing the progesterone receptor polyproline domain inhibits EGF signaling and cell proliferation in lung cancer cells
    Panthita Kaewjanthong, Sarintip Sooksai, Hironobu Sasano, György Hutvágner, Sarah Bajan, Eileen M. McGowan, Viroj Boonyaratanakornkit · 2022 · PLoS ONE
41. Quinoline–hydrazone hybrids as dual mutant EGFR inhibitors with promising metallic nanoparticle loading: rationalized design, synthesis, biological investigation and computational studies
    Ranza Elrayess, Khaled Mohamed Darwish, Mohamed S. Nafie, Gharieb S. El-Sayyed, Mohamed M. Said, Asmaa S. A. Yassen · 2022 · New Journal of Chemistry
42. Gatekeeper mutations activate FGF receptor tyrosine kinases by destabilizing the autoinhibited state
    Alida Besch, William M. Marsiglia, Moosa Mohammadi, Yingkai Zhang, Nathaniel J. Traaseth · 2023 · Proceedings of the National Academy of Sciences
43. Co-Conserved Features Associated with cis Regulation of ErbB Tyrosine Kinases
    Amar Mirza, Morad Mustafa, Eric Talevich, Natarajan Kannan · 2010 · PLoS ONE
44. EGFR tyrosine kinase targeted compounds: in vitro antitumor activity and molecular modeling studies of new benzothiazole and pyrimido[2,1-b]benzothiazole derivatives.
    Moustafa Tarek Gabr, Nadia S. El‐Gohary, Eman R. El‐Bendary, Mohamed M. El‐Kerdawy · 2014 · Europe PMC (PubMed Central)
45. Epidermal Growth Factor Receptor and its Trafficking Regulation by Acetylation: Implication in Resistance and Exploring the Newer Therapeutic Avenues in Cancer
    Manvendra Kumar, Gaurav Joshi, Joydeep Chatterjee, Raj Kumar · 2020 · Current Topics in Medicinal Chemistry
46. Structural Analysis of Interactions between Epidermal Growth Factor Receptor (EGFR) Mutants and Their Inhibitors
    Yingzhe Guo, Zeqian Du, Ting Shi · 2023 · Biophysica
47. Structural Mechanism and Inhibitors Targeting EGFR Exon 20 Insertion (Ex20ins) Mutations
    Hao Chen, Shiliang Hu, Adam Vorn Patterson, Jeff Bruce Smaill, Ke Ding, Xiaoyun Lu · 2023 · Journal of Medicinal Chemistry
48. Structural Analysis of the Macrocyclic Inhibitor BI‐4020 Binding to EGFR Kinase
    Tyler S. Beyett, Jaimin K. Rana, Ilse K. Schaeffner, David E. Heppner, Michael J. Eck · 2024 · ChemMedChem
49. Structure‐Guided Drug Design Targeting Abl Kinase: How Structure and Regulation Can Assist in Designing New Drugs
    Diego Magno Martins, Philipe Oliveira Fernandes, Lucas A. Vieira, Vinícius Gonçalves Maltarollo, Adolfo Henrique Moraes · 2024 · ChemBioChem
50. Traditional Chinese medicine as dual guardians against hypertension and cancer?
    Weng Ieong Tou, Calvin Yu‐Chian Chen · 2012 · Journal of Biomolecular Structure and Dynamics
51. Investigating molecular dynamics-guided lead optimization of EGFR inhibitors
    Martín J. Lavecchia, Raimon Puig de la Bellacasa, José Ignacio Borrell, Claudio N. Cavasotto · 2015 · Bioorganic & Medicinal Chemistry
52. Shedding light on complexity of protein–protein interactions in cancer
    Tae‐Young Yoon, Hong-Won Lee · 2019 · Current Opinion in Chemical Biology
53. A small-molecule compound D6 overcomes EGFR-T790M-mediated resistance in non-small cell lung cancer
    Xiaolong Tang, Lizhi Cheng, Li Guo, Yong‐Ming Yan, Fengting Su, Danling Huang, Shuping Zhang, Zuojun Liu, Minxian Qian, Ji Li et al. · 2021 · Communications Biology
54. Clinical outcomes of gefitinib and erlotinib in patients with NSCLC harboring uncommon EGFR mutations: A pooled analysis of 438 patients
    Chunsheng Wang, Kewei Zhao, Shanliang Hu, Dong Wei, Yan Qing Gong, Minghuan Li, Conghua Xie · 2022 · Lung Cancer
55. In silico screening of chalcone derivatives as promising EGFR-TK inhibitors for the clinical treatment of cancer
    Shalini Mathpal, Tushar Joshi, Priyanka Sharma, Priyanka Maiti, Mahesha Nand, Veena Pande, Subhash Chandra · 2023 · 3 Biotech
56. Multiple Consequences of a Single Amino Acid Pathogenic RTK Mutation: The A391E Mutation in FGFR3
    Fenghao Chen, Sarvenaz Sarabipour, Kalina A. Hristova · 2013 · PLoS ONE
57. Enhanced interrogation: emerging strategies for cell signaling inhibition
    Rong Huang, Isabel Martinez-Ferrando, Philip A. Cole · 2010 · Nature Structural & Molecular Biology
58. Potent and selective EGFR inhibitors based on 5-aryl-7H-pyrrolopyrimidin-4-amines
    Ann Christin Reiersølmoen, Thomas Ihle Aarhus, Sarah Eckelt, Kristin G. Nørsett, Eirik Sundby, Bård Helge Hoff · 2019 · Bioorganic Chemistry
59. Crystal structure, Hirshfeld, computational biomolecular investigations, and MTT assay studies of amino pyrimidine derivative as EGFR kinase domain inhibitor
    Ravikumar Chandrasekaran, S. Murugavel, Mridula Guin, Silambarasan Tamil Selvan · 2022 · Journal of Molecular Structure
60. The rapidly changing field of predictive biomarkers of non-small cell lung cancer
    László József Tóth, Attila Mokánszki, Gábor Méhes · 2024 · Pathology & Oncology Research
61. Evaluating the polypharmacological potential of cosmetic preservative Imidurea against Lung Cancer-associated EGFR, CDK2, STAT3, BCL2, p53, and ABCB1 proteins
    Shaban Ahmad, Khalid Raza · 2025 · International Journal of Biological Macromolecules
62. In Silico Study of Bis(6‐Amino‐1,3‐Dimethylpyrimidine‐2,4(1H,3H)‐Diones) as EGFR Inhibitors: Synthesis, DFT, Molecular Docking, and MD Simulation Studies
    Zeynab masoumi, Mohammad Bayat, Davood Gheidari · 2025 · Cellular Microbiology
63. Profiling and Optimizing Targeted Covalent Inhibitors through EGFR-Guided Studies
    Tahereh Damghani, Surbhi P. Chitnis, Omobolanle A. Abidakun, Kishan B. Patel, Kaly S. Lin, Emily A. Ouellette, Abigail M. Lantry, David E. Heppner · 2025 · Journal of Medicinal Chemistry
64. Targeting inosine metabolism to enhance EGFR-targeted therapy in lung adenocarcinoma
    Xiaolong Huang, Jiaqi Liang, Yanjun Yi, Junkan Zhu, Han Lin, Shencheng Ren, Cheng Tao, Guoshu Bi, Guangyao Shan, Dejun Zeng et al. · 2025 · Cancer Letters
65. Thiazole–driven heterocyclic hybrids as EGFR inhibitors: progress in synthesis and anticancer applications
    Ancilla Dsouza, V. M. Subrahmanyam, Nitinkumar S. Shetty · 2026 · RSC Advances
66. Decoding the EGFR mutation-induced drug resistance in lung cancer treatment by local surface geometric properties
    Lichun Ma, Debby D. Wang, Yiqing Huang, Maria Pik Wong, Victor Ho-Fun Lee, Hong Yan · 2014 · Computers in Biology and Medicine
67. Exploring the conformational landscapes of protein kinases: perspectives from FRET and DEER
    Zachary D. Baker, Damien M. Rasmussen, Nicholas M. Levinson · 2024 · Biochemical Society Transactions
68. Organocatalytic[3 + 2]Cycloaddition: Synthesis of Quinazoline Containing Sulfonyl 1,2,3‐Triazoles as Potent EGFR Targeting Anti‐Breast Cancer Agents
    Venkat Reddy Dodlapati, E. Ramya Sucharitha, Rambabu Palabindela, Ravikumar Kapavarapu, Sridhar Kavela, Sirassu Narsimha · 2024 · Journal of Heterocyclic Chemistry
69. Pharmacophore‐Based Modeling, Synthesis, and Biological Evaluation of Novel Quinazoline/Quinoline Derivatives: Discovery of EGFR Inhibitors with Low Nanomolar Activity
    Asaf Evrim Evren, Begüm Nurpelin Sağlık, Gülşen Akalın-Çiftçi, Leyla Yurttaş · 2024 · Advanced Theory and Simulations
70. Global hinge sites of proteins as target sites for drug binding
    Haotian Zhang, Mert Gür, İvet Bahar · 2024 · Proceedings of the National Academy of Sciences
71. Targeting mutant EGFR in non-small cell lung cancer in the context of cell adaptation and resistance
    Selene K. Roberts, Ioannis Galgadas, David T. Clarke, Laura C. Zanetti-Domingues, Francesco Luigi Gervasio, Marisa L. Martin-Fernandez · 2025 · Drug Discovery Today
72. Coupled mutation finder: A new entropy-based method quantifying phylogenetic noise for the detection of compensatory mutations
    Mehmet Gültaş, Martin Haubrock, Nesrin Tüysüz, Stephan Waack · 2012 · BMC Bioinformatics
73. Frequency, impact and a preclinical study of novel ERBB gene family mutations in HER2-positive breast cancer
    Naomi Elster, Sinéad Toomey, Yue Fan, Mattia Cremona, Clare Morgan, Karolina Weiner‐Gorzel, Úna Bhreathnach, Małgorzata Milewska, Madeline Murphy, Stephen F. Madden et al. · 2018 · Therapeutic Advances in Medical Oncology
74. Kinase inhibitors: An overview
    Sabeeha Ali, Manzar Alam, Md. Imtaiyaz Hassan · 2022 · Elsevier eBooks
75. Chemotherapy Drug Response to the L858R‐induced Conformational Change of EGFR Activation Loop in Lung Cancer
    Xi Ding, Xingcai Liu, Xiaoyun Song, Jun Yao · 2016 · Molecular Informatics
76. Synthesis and antitumor evaluation of novel 4‐anilino‐7,8‐dihydropyrido[4,3‐d]pyrimidine‐6(5H)‐carboxylate derivatives as potential EGFR inhibitors
    Dajun Zhang, Yan Yan, Ge Jin, Bo Liu, Xiaoliang Ma, Dan Han, Xiaojian Jia · 2018 · Archiv der Pharmazie
77. Mutation and drug-specific intracellular accumulation of EGFR predict clinical responses to tyrosine kinase inhibitors
    Maurice de Wit, Ya Gao, Darlene Mercieca, Iris J. de Heer, Bart Valkenburg, Martin E. van Royen, Joachim G.J.V. Aerts, Peter A.E. Sillevis Smitt, Pim J. French · 2020 · EBioMedicine
78. Quantitative Structure–Mutation–Activity Relationship Tests (QSMART) model for protein kinase inhibitor response prediction
    Liang‐Chin Huang, Wayland Yeung, Ye Wang, Huimin Cheng, Aarya Venkat, Sheng Li, Ping Ma, Khaled Rasheed, Natarajan Kannan · 2020 · BMC Bioinformatics
79. Anchor-based classification and type-C inhibitors for tyrosine kinases
    Kai‐Cheng Hsu, Tzu-Ying Sung, Chih-Ta Lin, Yi-Yuan Chiu, John T.-A. Hsu, Hui‐Chen Hung, Chung‐Ming Sun, Indrajeet J. Barve, Wenliang Chen, Wen-Chien Huang et al. · 2015 · Scientific Reports
80. Toward structure-based drug design against the epidermal growth factor receptor (EGFR)
    Yazan Haddad, Marek Remeš, Vojtěch Adam, Zbyněk Heger · 2020 · Drug Discovery Today
81. Synthesis of Novel Tetra-Substituted Pyrazole Derivatives Using Microwave Irradiation and Their Anti-Leukemic Activity Against Jurkat Cells
    Felipe P. Machado, Maria Clara Campos, Juliana Echevarria‐Lima, Diego Pereira Sangi, Carlos Serpa, Otávio Augusto Chaves, Aurea Echevarrı́a · 2025 · Molecules
82. The clathrin adaptor complex-1 and Rab12 regulate post-golgi trafficking of WT epidermal growth factor receptor (EGFR)
    Jinhui Wang, Pik Ki Lau, Chun Wa Li, Yusong Guo · 2023 · Journal of Biological Chemistry
83. The Role of Proteomics and Phosphoproteomics in the Discovery of Therapeutic Targets and Biomarkers in Acquired EGFR-TKI-Resistant Non-Small Cell Lung Cancer
    Sutpirat Moonmuang, Apichat Tantraworasin, Santhasiri Orrapin, Sasimol Udomruk, Busayamas Chewaskulyong, Dumnoensun Pruksakorn, Parunya Chaiyawat · 2023 · International Journal of Molecular Sciences
84. Analysis of cellular response to drugs with a microfluidic single-cell platform based on hyperspectral imaging
    Luyao Liu, Lulu Zhang, Xueyu Zhang, Xiaobin Dong, Xiaodan Jiang, Xiaoqi Huang, Wei Li, Xiaoming Xie, Xianbo Qiu · 2023 · Analytica Chimica Acta
85. Current management of uncommon EGFR mutations in non-small cell lung cancer
    Jonathan Q. Trinh, Omar Khaled Mahmoud Abughanimeh · 2024 · Current Problems in Cancer
86. A macrocyclic kinase inhibitor overcomes triple resistant mutations in EGFR-positive lung cancer
    Mai Suzuki, Ken Uchibori, Tomoko Oh‐hara, Yumi Nomura, Ryusei Suzuki, Ai Takemoto, Mitsugu Araki, Shigeyuki Matsumoto, Yukari Sagae, Mutsuko Kukimoto‐Niino et al. · 2024 · npj Precision Oncology
87. Discovery of potential epidermal growth factor receptor inhibitors from black pepper for the treatment of lung cancer: an in-silico approach
    Olusola Olalekan Elekofehinti, Ifeoluwa Racheal Adetoyi, Hannah Oluwaseun Popoola, Folasade Oluwatobiloba Ayodeji, Foluso Adeola Taiwo, Moses Orimoloye Akinjiyan, Omowunmi Funmilayo Koledoye, Opeyemi Iwaloye, Abayomi Emmanuel Adegboyega · 2024 · In Silico Pharmacology
88. Design, synthesis and evaluation of new methyl piperazine derivatives as anticancer agents
    Mahaveer Singh, Hemant R. Jadhav, Amit Choudhary, Pankaj K. Wadhwa · 2024 · Future Journal of Pharmaceutical Sciences
89. Traditional Chinese herbal formula, Fuzi-Lizhong pill, produces antidepressant-like effects in chronic restraint stress mice through systemic pharmacology
    Fangyi Zhao, Jingjing Piao, Jinfang Song, Zihui Geng, Hongyu Chen, Ziqian Cheng, Ranji Cui, Bingjin Li · 2024 · Journal of Ethnopharmacology
90. Immunotherapy in Oncogene-Addicted NSCLC: Evidence and Therapeutic Approaches
    Lorenzo Foffano, Elisa Bertoli, Martina Bortolot, Sara Torresan, Elisa De Carlo, Brigida Stanzione, Alessandro Del Conte, Fabio Puglisi, Michele Spina, Alessandra Bearz · 2025 · International Journal of Molecular Sciences
91. Advanced non-small-cell lung cancer with epidermal growth factor receptor mutations: current evidence and future perspectives
    Raffaele Costanzo, Agnese Montanino, Massimo Di Maïo, Maria Carmela Piccirillo, Claudia Sandomenico, Pasqualina Giordano, Gennaro Daniele, Renato Franco, Francesco Perrone, Gaetano Rocco et al. · 2013 · Expert Review of Anticancer Therapy
92. EGFR lung cancer mutants get specialized
    Peter Littlefield, Natalia Jura · 2013 · Proceedings of the National Academy of Sciences
93. Better Progression-Free Survival in Elderly Patients with Stage IV Lung Adenocarcinoma Harboring Uncommon Epidermal Growth Factor Receptor Mutations Treated with the First-line Tyrosine Kinase Inhibitors
    Ming‐Ju Tsai, Jen‐Yu Hung, Mei–Hsuan Lee, Chia‐Yu Kuo, Yu-Chen Tsai, Ying‐Ming Tsai, Ta‐Chih Liu, Chih‐Jen Yang, Ming‐Shyan Huang, Inn‐Wen Chong · 2018 · Cancers
94. Polyphenolics of purple devil fruits potentiate anti-inflammatory action by regulating the expression of inflammatory cytokines and apoptotic signaling molecules evident in extensive and combined experimental models
    A.S.M. Ali Reza, Md. Mamunur Rashid, Md. Shahidul Islam, Md. Amjad Hossen, A. M. Abu Ahmed, Md. Anwarul Haque, Shamima Nasrin, Md. Nazim Uddin, Jishan Khan, Md. Atiar Rahman · 2023 · Journal of Functional Foods
95. Synthesis and evaluation of 4-anilinoquinazoline bioisosteres as potential anti-breast cancer agents
    Afaf K. El-Ansary, Aliaa M. Kamal, Mokhtar AbdHafiz Al-Ghorafi · 2014 · European Journal of Medicinal Chemistry
96. Identification of novel drug-resistant EGFR mutant inhibitors by in silico screening using comprehensive assessments of protein structures
    Tomohiro Sato, Hisami Watanabe, Keiko Tsuganezawa, Hitomi Yuki, Junko Mikuni, Seiko Yoshikawa, Mutsuko Kukimoto‐Niino, Takako Fujimoto, Yumiko Terazawa, Motoaki Wakiyama et al. · 2012 · Bioorganic & Medicinal Chemistry
97. Antitumor Impact of p14ARF on Gefitinib-Resistant Non–Small Cell Lung Cancers
    Ken Saito, Nagio Takigawa, Naoko Ohtani, H Iioka, Yuki Tomita, Ryuzo Ueda, Junya Fukuoka, K. Kuwahara, Eiki Ichihara, Katsuyuki Kiura et al. · 2013 · Molecular Cancer Therapeutics
98. Knockdown of the Epidermal Growth Factor Receptor Gene to Investigate Its Therapeutic Potential for the Treatment of Non–Small-Cell Lung Cancers
    Kazuhiko Shien, Tsuyoshi Ueno, Kazunori Tsukuda, Junichi Soh, Kenichi Suda, Takafumi Kubo, Masashi Furukawa, Takayuki Muraoka, Yuho Maki, Norimitsu Tanaka et al. · 2012 · Clinical Lung Cancer
99. HTRF Kinase Assay Development and Methods in Inhibitor Characterization
    Yong Jia, Mari Manuia, Jose Juarez · 2015 · Methods in molecular biology
100. Natural Products as Chemopreventive Agents by Potential Inhibition of the Kinase Domain in ErbB Receptors
     Maria Olivero-Acosta, W. Maldonado-Rojas, J. Olivero-Verbel · 2017 · Molecules